FLINT, Mich., Aug. 14, 2017 /PRNewswire/
-- EnvoyHealth, a Diplomat company, has agreed to a
co-marketing partnership with PharMedQuest for its ARC™ medical
benefit drug management platform.
PharMedQuest's ARC™ program platform will provide EnvoyHealth an
advanced solution for managing high-cost oncology drug
medications.
ARC™ enables payors and providers to optimize clinical and
financial outcomes for treatment of cancer conditions. Through
state-of-the art technology and clinical expertise, it offers
real-time data that optimally manages oncology therapy under the
medical benefit. In partnership, EnvoyHealth and PharMedQuest
provide comprehensive oncology management solutions under the
pharmacy benefit and medical benefit.
"We are thrilled to expand our service expertise and portfolio
by partnering with PharMedQuest," said Atheer Kaddis, EnvoyHealth's executive vice
president of sales and strategic alignment. "Our full-service model
allows us to customize solutions for our partners to demonstrate
value, cost-effectiveness, and outcomes to manage the oncology
marketplace dynamics. EnvoyHealth's enhanced service offerings will
help our partners meet their objectives in a way that delivers real
value."
"We are excited to partner with EnvoyHealth on this new
strategic initiative providing a uniquely innovative approach to
managing high-cost oncology drugs," said Kirby Eng, vice president of business
development at PharMedQuest. "Integrating ARC™ with EnvoyHealth's
depth and breadth of complementary specialty drug dispensing,
clinical, and patient care management capabilities will enable
payors and plan sponsors to collaborate with providers to ensure
clinical and cost-effective utilization of high-cost oncology
medications for patients afflicted with cancer."
To learn more about EnvoyHealth, visit envoyhealth.is.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2016, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) is the nation's largest independent
provider of specialty pharmacy services—helping patients and
providers in all 50 states. The company offers medication
management programs for people with complex chronic diseases and
delivers unique solutions for manufacturers, hospitals, payors,
providers, and more. Diplomat opened its doors in 1975 as a
neighborhood pharmacy with one essential tenet: "Take good care of
patients and the rest falls into place." Today, that tradition
continues—always focused on improving patient care and clinical
adherence. For more information, visit diplomat.is.
About EnvoyHealth
EnvoyHealth provides customized services to support
pharmaceutical and medical-device manufacturers, payors, hospitals,
and health care providers and service organizations. We leverage
industry and management expertise to meet the challenges of our
clients and the patients they serve. Clients choose us because we
are an integral part of their team, tailoring our scalable approach
to craft solutions unique to their brand-specific needs and
strategic timelines.
EnvoyHealth significantly expanded its offerings through the
recent acquisition of WRB Communications Inc. WRB complements
EnvoyHealth's reimbursement hub, noncommercial pharmacy, and
clinical research capabilities and adds medical information, remote
patient monitoring, inside sales, and customer care capabilities.
To learn more about EnvoyHealth, visit envoyhealth.is.
About PharMedQuest
PharMedQuest, an Inc. 5000 company, delivers the highest
cost-effective care to patients by investing in optimal resources
to build transformational & innovative tools, knowledge, and
management for clinicians & payors. Our consulting experience
allows us to provide the most robust process, comprehensive insight
and sustainable value for our clients. PharMedQuest is ACHC
accredited with a distinction in oncology and services include ARC™
medical benefit management, P340B®management, ACE acute
& chronic disease patient management and specialty pharmacy
services. For more information about PharMedQuest call (714)
364-4008 or visit PharMedQuest.com.
CONTACT:
Kali Lucas, Public Relations
Specialist
810.768.9580 | press@diplomat.is
Atheer Kaddis, Executive Vice
President,
Sales and Strategic Alignment
810.768.9519 | akaddis@diplomat.is
View original content with
multimedia:http://www.prnewswire.com/news-releases/envoyhealth-partners-with-health-care-management-company-pharmedquest-300503305.html
SOURCE EnvoyHealth, a Diplomat company